A Label-free Extracellular-vesicle Automated Purification System (LEAP System)

无标记细胞外囊泡自动纯化系统（LEAP系统）

基本信息

批准号：
10324624
负责人：
Yuchao Chen
金额：
$ 19.75万
依托单位：
WELLSIM BIOMEDICAL TECHNOLOGIES, INC.
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-01 至 2022-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10324624
关键词：
Acoustics Address Adoption Affinity Biological Biological Markers Biological Sciences Biomedical Technology Blood Plasma Volume Cell Culture Techniques Cells Chromatography Clinical Collaborations Complex Consumption Data Density Gradient Centrifugation Development Devices Diagnosis Diagnostic Disease Early Diagnosis Encapsulated Ensure Evaluation Goals Knowledge Label Lipid Bilayers Lipids Liquid substance Medicine Membrane Methods Microfluidics Nucleic Acids Outcome Parents Performance Phase Plasma Precipitation Process Prognosis Proteins Publications Reagent Recovery Research Research Personnel Saliva Sampling Scientist Small Business Innovation Research Grant Source Speed System Technology Testing Time Transducers Translations Ultracentrifugation Ultrafiltration Urine Work base cell type clinical application clinical translation cost cost effective design expectation extracellular vesicles flexibility improved innovation innovative technologies magnetic field nanoparticle new technology next generation novel novel strategies particle precision medicine pressure processing speed prototype scale up success technological innovation tool

项目摘要

PROJECT SUMMARY / ABSTRACT Extracellular vesicles (EVs) are small lipid bilayer particles secreted by most cell types, which encapsulates biomolecules including lipids, proteins, and nucleic acids from parent cells. Profiling of EV-derived biomarkers provides a promising approach for early diagnoses and prognosis of various diseases. Currently, one of the primary hindrances to the implementation and usage of EVs is lack of a robust method for convenient and high- speed isolation of EVs with high yield and purity. A number of recent publications mentioned that developing efficient and reliable isolation methods is urgent to further advance in this field. There is a strong desire to explore innovated technologies for better performance of EV isolation in terms of throughput, purity, yield, speed, robustness, and cost. To overcome these challenges, WellSIM Biomedical Technologies proposes to develop, optimize, and validate a Label-free Extracellular-vesicle Automated Purification System (LEAP System) for EV isolation from bodily fluids (e.g., plasma and urine) with excellent performance. Based on our current prototype which has shown competitive EV yield, purity, and isolation efficiency, we will further improve the processing speed, sample volume load, and throughput by redesigning and optimizing the System. Our preliminary studies support that, with the proposed improvement, we can expect to simultaneously isolate EVs from up to 6 plasma samples (>2 mL) within 1 hr with purity and yield outperform other EV isolation methods. After system upgrade and optimization, we will comprehensively validate our next-generation platform with cell culture medium, urine, and plasma in terms of yield, purity, speed, and processing volume. Our new platform will directly address the current bottlenecks, and thus provide an advanced EV purification tool for EV-based life science and precision medicine.

项目概要/摘要细胞外囊泡 (EV) 是大多数细胞类型分泌的小型脂质双层颗粒，其封装生物分子，包括来自亲本细胞的脂质、蛋白质和核酸。 EV 衍生生物标志物的分析为各种疾病的早期诊断和预后提供了一种有前景的方法。目前，其中之一电动汽车的实施和使用的主要障碍是缺乏一种可靠的方法来方便和高效以高产量和纯度快速分离 EV。最近的一些出版物提到，发展高效可靠的隔离方法亟待进一步推进该领域。有强烈的探索欲望创新技术可在吞吐量、纯度、产量、速度、鲁棒性和成本。为了克服这些挑战，WellSIM Biomedical Technologies 建议开发，优化并验证用于 EV 的无标记细胞外囊泡自动纯化系统（LEAP 系统）与体液（例如血浆和尿液）的分离具有优异的性能。基于我们当前的原型它已显示出具有竞争力的 EV 产量、纯度和隔离效率，我们将进一步改进处理通过重新设计和优化系统来提高速度、样品体积负载和吞吐量。我们的初步研究支持，通过拟议的改进，我们可以期望同时将电动汽车与多达 6 个等离子体隔离 1 小时内获得样品 (>2 mL)，其纯度和产量优于其他 EV 分离方法。系统升级后和优化，我们将用细胞培养基、尿液、以及等离子体在产量、纯度、速度和处理量方面的优势。我们的新平台将直接解决解决目前的瓶颈，从而为基于电动汽车的生命科学和精密提供先进的电动汽车净化工具药品。